Translational Oncology Division, OncoHealth Institute, Health Research Institute - University Hospital "Fundación Jiménez Díaz"-UAM, Av. Reyes Católicos 2, 28040, Madrid, Spain.
Department of Pathology, Clinico San Carlos University Hospital, Madrid, Spain.
BMC Cancer. 2018 Feb 6;18(1):144. doi: 10.1186/s12885-018-4048-8.
Limited data are available regarding the ability of biomarkers to predict complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Complete response translates to better patient survival. DEK is a transcription factor involved not only in development and progression of different types of cancer, but is also associated with treatment response. This study aims to analyze the role of DEK in complete pathological response following chemoradiotherapy for locally advanced rectal cancer.
Pre-treated tumour samples from 74 locally advanced rectal-cancer patients who received chemoradiation therapy prior to total mesorectal excision were recruited for construction of a tissue microarray. DEK immunoreactivity from all samples was quantified by immunohistochemistry. Then, association between positive stained tumour cells and pathologic response to neoadjuvant treatment was measured to determine optimal predictive power.
DEK expression was limited to tumour cells located in the rectum. Interestingly, high percentage of tumour cells with DEK positiveness was statistically associated with complete pathological response to neoadjuvant treatment based on radiotherapy and fluoropyrimidine-based chemotherapy and a marked trend toward significance between DEK positiveness and absence of treatment toxicity. Further analysis revealed an association between DEK and the pro-apoptotic factor P38 in the pre-treated rectal cancer biopsies.
These data suggest DEK as a potential biomarker of complete pathological response to treatment in locally advanced rectal cancer.
关于生物标志物预测局部晚期直肠癌新辅助放化疗完全病理缓解的能力，相关数据有限。完全缓解意味着患者的生存状况更好。DEK 是一种转录因子，不仅参与多种癌症的发生和发展，还与治疗反应有关。本研究旨在分析 DEK 在局部晚期直肠癌新辅助放化疗后完全病理缓解中的作用。
从 74 例接受全直肠系膜切除术前行新辅助放化疗的局部晚期直肠癌患者的预处理肿瘤样本中招募构建组织微阵列。采用免疫组织化学法对所有样本的 DEK 免疫反应进行定量。然后，测量阳性染色肿瘤细胞与新辅助治疗病理反应之间的关联，以确定最佳预测能力。
DEK 表达仅限于位于直肠的肿瘤细胞。有趣的是，根据放疗和氟嘧啶为基础的化疗，高比例的肿瘤细胞呈 DEK 阳性与新辅助治疗的完全病理缓解具有统计学关联，并且在 DEK 阳性与治疗毒性缺失之间存在显著的趋势。进一步的分析显示，DEK 与预处理直肠癌活检中的促凋亡因子 P38 之间存在关联。
这些数据表明 DEK 可作为局部晚期直肠癌治疗完全病理缓解的潜在生物标志物。
